Publications
209
Citations
18,155
Est. group size
—
Recurring co-author estimate
Active years
51
Publishing since 1975
Typically publishes in teams of ~12 · 3% small-team papers (≤3 authors) · across 11 venues
- Frederick R. Singer, MD (1939-2025)
Journal of Bone and Mineral Research · 2025
- Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism
Journal of the Endocrine Society · 2023
- Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial
Journal of Bone and Mineral Research · 2020
- Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis
Current Medical Research and Opinion · 2020
- Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
The Lancet Diabetes & Endocrinology · 2019
- Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
Osteoporosis International · 2019
- Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates
Osteoporosis International · 2019
- Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism
The Journal of Clinical Endocrinology & Metabolism · 2019
- OR30-1 Safety and Efficacy of Recombinant Human Parathyroid Hormone 1-84 for the Treatment of Adults with Chronic Hypoparathyroidism: Six-Year Results of the RACE Study
Journal of the Endocrine Society · 2019
- Recombinant human parathyroid hormone 1-84 for the treatment of adults with chronic hypoparathyroidism: Six-year safety and efficacy results of the RACE study
Endocrine Abstracts · 2019
- Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism
2019
- Abstract #221 Safety and Efficacy of Recombinant Human Parathyroid Hormone 1-84 for the Treatment of Adults with Chronic Hypoparathyroidism: six-Year Results of the Race Study
Endocrine Practice · 2019
- OR30-1 Safety and Efficacy of Recombinant Human Parathyroid Hormone 1-84 for the Treatment of Adults with Chronic Hypoparathyroidism: Six-Year Results of the RACE Study
2019
- Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
Journal of Bone and Mineral Research · 2018
- ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
The Journal of Clinical Endocrinology & Metabolism · 2018
- Figshare×8
- Osteoporosis International×5
- Journal of Bone and Mineral Research×4
- The Lancet Diabetes & Endocrinology×3
- The Journal of Clinical Endocrinology & Metabolism×3
- Matthew R. Allen
Medicine · Indiana University
- Joseph M. Wallace
Medicine · Purdue University West Lafayette
- Amy Creecy
Medicine · Indiana University
- C. Conrad Johnston
Medicine · Indiana University
- David B. Burr
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile